|
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results. |
|
Bhagirathbhai R. Dholaria |
Stock and Other Ownership Interests - Iovance Biotherapeutics; Syndax |
Honoraria - Adaptive Biotechnologies; Curio Science; MJH Healthcare Holdings, LLC; Wiley |
Consulting or Advisory Role - arivan research; Beam Therapeutics; Gamida Cell; Jazz Pharmaceuticals; Pluristem Therapeutics |
Research Funding - Angiocrine Bioscience (Inst); Janssen Oncology (Inst); MEI Pharma (Inst); Orca Bio (Inst); Pfizer (Inst); poseida therapeutics (Inst); Takeda (Inst); WUGEN, Inc. (Inst) |
|
|
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene (Inst); Celgene; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Janssen-Cilag; Karyopharm Therapeutics; Novartis; Oncopeptides; Pfizer; Roche; Sanofi; Sanofi (Inst); Takeda |
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Oncopeptides; Roche; Sanofi; Takeda |
Research Funding - Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Takeda |
|
|
Honoraria - Abbvie/Genentech; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Sanofi; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Pfizer; Regeneron; Roche/Genentech; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Chugai Pharma; GlaxoSmithKline; Janssen-Cilag; Novartis; Pfizer; Sanofi |
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Janssen-Cilag (Inst); Sanofi (Inst) |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); GlycoMimetics Inc. (Inst); Heidelberg Pharma (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); MorphoSys (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen-Cilag; Novartis; Pfizer; Sanofi |
Other Relationship - Amgen (Inst); Array BioPharma/Pfizer (Inst); Celgene/Bristol-Myers Squibb (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Mundipharma (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - GlaxoSmithKline; Legend Biotech |
Research Funding - AMGEN (Inst); Janssen Oncology (Inst); Sanofi (Inst) |
|
|
Honoraria - Abbvie; Takeda |
Travel, Accommodations, Expenses - Janssen Oncology |
|
|
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda |
Consulting or Advisory Role - Janssen |
Research Funding - Bristol-Myers Squibb; Janssen |
|
|
Honoraria - Abbvie; Celgene; GlaxoSmithKline; H3 Biomedicine; Janssen; Pfizer; Sanofi |
Consulting or Advisory Role - Abbvie; BMS; GlaxoSmithKline; Janssen; Pfizer; Sanofi |
Speakers' Bureau - BMS; GlaxoSmithKline; Janssen; Sanofi |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Akcea Therapeutics; Bristol-Myers Squibb/Celgene; Janssen Oncology; Pfizer; Prothena |
Research Funding - Abbvie (Inst); Caelum Biosciences (Inst); Janssen Oncology (Inst); Prothena (Inst); Regeneron (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Takeda (Inst); TeneoBio (Inst) |
Travel, Accommodations, Expenses - Imbrium Therapeutics |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi |
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi |
|
|
Honoraria - Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Sanofi |
|
|
Honoraria - Abbvie; Amgen; Celgene; Genentech/Roche; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda |
Research Funding - Celgene (Inst); Janssen (Inst) |
|
|
Employment - GlaxoSmithKline; Janssen |
Stock and Other Ownership Interests - GlaxoSmithKline; Janssen |
|
|
Employment - Janssen; Merck (I) |
Stock and Other Ownership Interests - Janssen; Merck (I) |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Janssen Research & Development |
|
|
Employment - Amgen; Janssen Biologics BV; Johnson & Johnson |
Stock and Other Ownership Interests - Amgen; Johnson & Johnson |
|
|
Honoraria - Abbvie; Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Janssen (Inst); Kite/Gilead (Inst); Pfizer (Inst); Sanofi (Inst) |
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Janssen (Inst); Kite/Gilead (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst) |
Research Funding - Janssen (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Gilead Sciences; Janssen |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bayer (Inst); Bristol Myers Squibb Foundation (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst); Takeda (Inst) |
Research Funding - Amgen (Inst); Bristol Myers Squibb Foundation (Inst); Celgene (Inst); Cellectis (Inst); Janssen (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Antengene; Bristol-Myers Squibb/Celgene; Genentech; Genzyme; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; OncoPeptides; Seagen; Secura Bio; Shattuck Labs; Takeda |
Research Funding - Amgen; Celgene; Janssen; Pharmacyclics; Seagen; Takeda |